Long Term Debt Summary of Emergent BioSolutions Inc.

Emergent BioSolutions Inc.'s latest annual long term debt in 2023 was 446.5 Million USD , down -0.45% from previous year.
Emergent BioSolutions Inc.'s latest quarterly long term debt in 2024 Q2 was 447 Million USD , up 0.07% from previous quarter.
Emergent BioSolutions Inc. reported annual long term debt of 448.5 Million USD in 2022, down -44.59% from previous year.
Emergent BioSolutions Inc. reported annual long term debt of 809.4 Million USD in 2021, down -3.76% from previous year.
Emergent BioSolutions Inc. reported quarterly long term debt of 446.7 Million USD for 2024 Q1, up 0.04% from previous quarter.
Emergent BioSolutions Inc. reported quarterly long term debt of 447.7 Million USD for 2023 Q1, down -0.18% from previous quarter.

Annual Long Term Debt Chart of Emergent BioSolutions Inc. (2023 - 2001)

Historical Annual Long Term Debt of Emergent BioSolutions Inc. (2023 - 2001)

Year	Long Term Debt	Long Term Debt Growth
2023	446.5 Million USD	-0.45%
2022	448.5 Million USD	-44.59%
2021	809.4 Million USD	-3.76%
2020	841 Million USD	5.34%
2019	798.4 Million USD	1.77%
2018	784.5 Million USD	5729.68%
2017	13.45 Million USD	-94.58%
2016	248.09 Million USD	-1.94%
2015	253 Million USD	0.8%
2014	251 Million USD	304.84%
2013	62 Million USD	6.34%
2012	58.3 Million USD	7.78%
2011	54.09 Million USD	78.89%
2010	30.23 Million USD	-32.69%
2009	44.92 Million USD	25.02%
2008	35.93 Million USD	-15.62%
2007	42.58 Million USD	35.77%
2006	31.36 Million USD	198.69%
2005	10.5 Million USD	-11.16%
2004	11.82 Million USD	0.0%
2002	- USD	0.0%
2001	- USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	447 Million USD	0.07%
2024 Q1	446.7 Million USD	0.04%
2023 Q1	447.7 Million USD	-0.18%
2023 Q3	448.2 Million USD	0.04%
2023 Q2	448 Million USD	0.07%
2023 FY	446.5 Million USD	-0.45%
2023 Q4	446.5 Million USD	-0.38%
2022 FY	448.5 Million USD	-44.59%
2022 Q2	793.6 Million USD	-0.99%
2022 Q1	801.5 Million USD	-0.98%
2022 Q3	1.03 Billion USD	30.05%
2022 Q4	448.5 Million USD	-56.54%
2021 Q2	825.2 Million USD	-0.95%
2021 Q1	833.1 Million USD	-0.94%
2021 Q4	809.4 Million USD	-0.97%
2021 Q3	817.3 Million USD	-0.96%
2021 FY	809.4 Million USD	-3.76%
2020 Q4	841 Million USD	-0.88%
2020 FY	841 Million USD	5.34%
2020 Q1	762.9 Million USD	-4.45%
2020 Q2	758.1 Million USD	-0.63%
2020 Q3	848.5 Million USD	11.92%
2019 Q2	830.4 Million USD	13.38%
2019 Q1	732.4 Million USD	-6.64%
2019 FY	798.4 Million USD	1.77%
2019 Q3	813.3 Million USD	-2.06%
2019 Q4	798.4 Million USD	-1.83%
2018 FY	784.5 Million USD	5729.68%
2018 Q1	13.46 Million USD	0.09%
2018 Q2	13.48 Million USD	0.1%
2018 Q4	784.5 Million USD	5713.26%
2018 Q3	13.49 Million USD	0.1%
2017 Q4	13.45 Million USD	-94.6%
2017 Q2	248.69 Million USD	0.12%
2017 FY	13.45 Million USD	-94.58%
2017 Q1	248.39 Million USD	0.12%
2017 Q3	248.99 Million USD	0.12%
2016 Q3	247.79 Million USD	0.16%
2016 FY	248.09 Million USD	-1.94%
2016 Q4	248.09 Million USD	0.12%
2016 Q2	247.39 Million USD	0.08%
2016 Q1	247.19 Million USD	-2.3%
2015 Q4	253 Million USD	0.0%
2015 Q2	253 Million USD	0.8%
2015 Q1	251 Million USD	0.0%
2015 FY	253 Million USD	0.8%
2015 Q3	253 Million USD	0.0%
2014 Q2	251 Million USD	0.0%
2014 FY	251 Million USD	304.84%
2014 Q3	251 Million USD	0.0%
2014 Q1	251 Million USD	304.84%
2014 Q4	251 Million USD	0.0%
2013 Q1	57.18 Million USD	-1.92%
2013 Q3	54.95 Million USD	-1.99%
2013 Q2	56.06 Million USD	-1.95%
2013 Q4	62 Million USD	12.83%
2013 FY	62 Million USD	6.34%
2012 FY	58.3 Million USD	7.78%
2012 Q2	58.14 Million USD	0.95%
2012 Q3	58.86 Million USD	1.25%
2012 Q4	58.3 Million USD	-0.95%
2012 Q1	57.59 Million USD	6.47%
2011 Q2	29.07 Million USD	-1.97%
2011 FY	54.09 Million USD	78.89%
2011 Q1	29.65 Million USD	-1.92%
2011 Q3	48.87 Million USD	68.1%
2011 Q4	54.09 Million USD	10.68%
2010 FY	30.23 Million USD	-32.69%
2010 Q2	36.91 Million USD	-16.43%
2010 Q1	44.16 Million USD	-1.7%
2010 Q4	30.23 Million USD	-16.52%
2010 Q3	36.22 Million USD	-1.86%
2009 Q1	35.2 Million USD	-2.02%
2009 Q4	44.92 Million USD	119.16%
2009 FY	44.92 Million USD	25.02%
2009 Q3	20.5 Million USD	-3.53%
2009 Q2	21.25 Million USD	-39.64%
2008 Q3	39.65 Million USD	-2.35%
2008 Q2	40.6 Million USD	-2.63%
2008 Q1	41.7 Million USD	-2.08%
2008 FY	35.93 Million USD	-15.62%
2008 Q4	35.93 Million USD	-9.37%
2007 Q4	42.58 Million USD	-2.07%
2007 FY	42.58 Million USD	35.77%
2007 Q2	30.02 Million USD	-2.36%
2007 Q1	30.74 Million USD	-1.98%
2007 Q3	43.48 Million USD	44.86%
2006 FY	31.36 Million USD	198.69%
2006 Q4	31.36 Million USD	-3.65%
2006 Q3	32.55 Million USD	0.0%
2005 Q4	10.5 Million USD	0.0%
2005 FY	10.5 Million USD	-11.16%
2004 FY	11.82 Million USD	0.0%
2004 Q4	11.82 Million USD	0.0%
2002 FY	- USD	0.0%
2001 Q4	- USD	0.0%
2001 FY	- USD	0.0%
2000 Q4	- USD	0.0%

Peer Long Term Debt Comparison of Emergent BioSolutions Inc.

Name	Long Term Debt	Long Term Debt Difference
Amneal Pharmaceuticals, Inc.	2.52 Billion USD	82.302%
Bausch Health Companies Inc.	21.93 Billion USD	97.965%
Catalent, Inc.	4.54 Billion USD	90.176%
Elanco Animal Health Incorporated	5.73 Billion USD	92.216%
Perrigo Company plc	3.63 Billion USD	87.709%
Teva Pharmaceutical Industries Limited	18.48 Billion USD	97.584%
Zoetis Inc.	6.56 Billion USD	93.198%

Global Stocks Search

Emergent BioSolutions Inc. (EBS)

Long Term Debt Summary of Emergent BioSolutions Inc.

Annual Long Term Debt Chart of Emergent BioSolutions Inc. (2023 - 2001)

Historical Annual Long Term Debt of Emergent BioSolutions Inc. (2023 - 2001)

Peer Long Term Debt Comparison of Emergent BioSolutions Inc.